Cargando…
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
Systemic mastocytosis (SM) is a rare clonal hematologic neoplasm, driven, in almost all cases, by the activating KIT D816V mutation that leads to the growth and accumulation of neoplastic mast cells. While patients with advanced forms of SM have a poor prognosis, the introduction of KIT inhibitors (...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001403/ https://www.ncbi.nlm.nih.gov/pubmed/33804174 http://dx.doi.org/10.3390/ijms22062983 |